ME02490B - Hemijska jedinjenja - Google Patents
Hemijska jedinjenjaInfo
- Publication number
- ME02490B ME02490B MEP-2016-160A MEP16016A ME02490B ME 02490 B ME02490 B ME 02490B ME P16016 A MEP16016 A ME P16016A ME 02490 B ME02490 B ME 02490B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- compound according
- salt
- humans
- prevention
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 21
- 150000003839 salts Chemical class 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (20)
1.Jedinjenje formule Igde je R1 H, Cl, Br, N(CH3)2, ili metoksi;R2 je H ili OH;svaki R3 je nezavisno C1-6alkil;X je CH2, C(O), ili CH=CH;Q je C0-6alkil;R4 je NR5R5; gde je jedan R5 H, a drugi je CH2CO2H, CH2SO3H, CH2CH2SO3H, ili CH(R7)C0-1alkiCO2H.R7 je C0-6alkilCO2H, C0-6alkilOH, C0-6alkilSO3H ili C0-6alkilPO3H2.
2.Jedinjenje prema zahtevu 1, što je R1 metoksi.
3.Jedinjenje prema bilo kom od prethodnih zahteva , što je R2 H.
4.Jedinjenje prema bilo kom od zateva 1-3, što je X CH2.
5.Jedinjenje prema bilo kom od prethodnih zahteva, što je X C(O).
6.Jedinjenje prema bilo kom od prethodnih zahteva, što je Q C0-2alkil.
7.Jedinjenje prema bilo kom od prethodnih zahteva, što je Q C0alkil (tj. odsutan je).
8.Jedinjenje prema bilo kom od prethodnih zahteva, što je svaki R3 nezavisno C2-4alkil.
9.Jedinjenje prema bilo kom od prethodnih zahteva, što je svaki R3 nezavisno etil ili n-butil.
10.Jedinjenje prema bilo kom od prethodnih zahteva, što je R7 C0-1alkilCO2H ili C0-2alkilSO3H.
11.Jedinjenje prema zahtevu 1, što je
12.Jedinjenje prema zahtevu 1, što je
13.Jedinjenje prema zahtevu 12, što je pomenuno jedinjenje kristalno.
14.Farmaceutski prihvatljiva so jedinjenja prema bilo kom od prethodnih zahteva.
15. Farmaceutska kompozicija koja sadrži jedinjenje ili so prema zahtevima 1-14.
16.Farmaceutska kompozicija prema zahtevu 15 za upotrebu u lečenju ili prevenciji metaboličkog poremećaja kod ljudi.
17.Jedinjenje ili so definisano u bilo kom od zahteva 1-14 za upotrebu u lečenju ili prevenciji metaboličkog poremećaja kod ljudi.
18.Upotreba jedinjenja ili soli prema zahtevu 17, što je pomenuti metabolički poremećaj šećerna bolest (tipa I i tipa II) ili gojaznost.
19.Jedinjenje ili so definisano prema bilo kom od zahteva 1-14 za upotrebu u terapiji.
20. Upotreba jedinjenja ili soli definisanog prema bilo kom od zahtevu 1-14 u proizvodnji leka za lečenje ili prevenciju metaboličkog poremećaja kod ljudi.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32821210P | 2010-04-27 | 2010-04-27 | |
| US32922510P | 2010-04-29 | 2010-04-29 | |
| EP11775513.2A EP2563122B1 (en) | 2010-04-27 | 2011-04-27 | Chemical compounds |
| PCT/US2011/034024 WO2011137135A1 (en) | 2010-04-27 | 2011-04-27 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02490B true ME02490B (me) | 2017-02-20 |
Family
ID=44861895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-160A ME02490B (me) | 2010-04-27 | 2011-04-27 | Hemijska jedinjenja |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US9040518B2 (me) |
| EP (1) | EP2563122B1 (me) |
| JP (1) | JP5702853B2 (me) |
| KR (1) | KR101769079B1 (me) |
| CN (1) | CN102858159B (me) |
| AR (1) | AR081337A1 (me) |
| AU (1) | AU2011245393B2 (me) |
| BR (1) | BR112012026767B1 (me) |
| CA (1) | CA2795543C (me) |
| CL (1) | CL2012003009A1 (me) |
| CO (1) | CO6612267A2 (me) |
| CR (1) | CR20120557A (me) |
| CY (1) | CY1118187T1 (me) |
| DK (1) | DK2563122T3 (me) |
| DO (1) | DOP2012000263A (me) |
| EA (1) | EA021753B1 (me) |
| ES (1) | ES2588743T3 (me) |
| HR (1) | HRP20161103T1 (me) |
| HU (1) | HUE029480T2 (me) |
| IL (1) | IL222365A (me) |
| JO (1) | JO3131B1 (me) |
| LT (1) | LT2563122T (me) |
| MA (1) | MA34235B1 (me) |
| ME (1) | ME02490B (me) |
| MX (1) | MX2012012527A (me) |
| MY (1) | MY162933A (me) |
| NZ (1) | NZ602754A (me) |
| PE (1) | PE20130384A1 (me) |
| PH (1) | PH12012502128B1 (me) |
| PL (1) | PL2563122T3 (me) |
| PT (1) | PT2563122T (me) |
| RS (1) | RS55079B1 (me) |
| SG (1) | SG184812A1 (me) |
| SI (1) | SI2563122T1 (me) |
| SM (1) | SMT201600293B (me) |
| UA (1) | UA110338C2 (me) |
| UY (1) | UY33353A (me) |
| WO (1) | WO2011137135A1 (me) |
| ZA (1) | ZA201207858B (me) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57778B1 (sr) | 2010-11-04 | 2018-12-31 | Albireo Ab | Inhibitori crevnog transportera žučne kiseline (ibat) za lečenje bolesti jetre |
| US8889657B2 (en) | 2011-08-31 | 2014-11-18 | Mallinckrodt Llc | Nanoparticle PEG modification with H-phosphonates |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CN105263957A (zh) | 2013-05-02 | 2016-01-20 | 葛兰素史克知识产权开发有限公司 | 治疗肽 |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| US9834529B2 (en) | 2014-08-05 | 2017-12-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Synthesis of benzothiazepines |
| KR101674806B1 (ko) * | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| CN107873023B (zh) | 2015-02-02 | 2021-07-23 | 福马治疗股份有限公司 | 作为hdac抑制剂的3-烷基-4-酰氨基-双环[4，5，0]异羟肟酸 |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
| JP7094899B2 (ja) * | 2016-06-27 | 2022-07-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド | 合成方法 |
| EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP7391048B2 (ja) | 2018-06-05 | 2023-12-04 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| MX2020013774A (es) | 2018-06-20 | 2021-03-02 | Albireo Ab | Modificaciones de cristales de odevixibat. |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| JP7504109B2 (ja) | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN113453753B (zh) | 2019-02-06 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| WO2020167981A1 (en) | 2019-02-12 | 2020-08-20 | Mirum Pharmaceuticals, Inc. | Methods for increasing growth in pediatric subjects having cholestatic liver disease |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CN114761080B (zh) * | 2019-12-04 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2021110884A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| WO2021110885A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| PT4069360T (pt) * | 2019-12-04 | 2024-03-06 | Albireo Ab | Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4232043A1 (en) | 2020-10-20 | 2023-08-30 | GlaxoSmithKline Intellectual Property (No.2) Limited | Methods for treating cholestatic pruritus |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CN116583504A (zh) | 2020-12-04 | 2023-08-11 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US20240391885A1 (en) | 2020-12-23 | 2024-11-28 | Glaxosmithkline Intellectual Property (No. 2) Limited | Forms of linerixibat |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| JP2025516153A (ja) | 2022-04-22 | 2025-05-27 | アルビレオ・アクチボラグ | Ａｓｂｔ阻害剤の皮下投与 |
| JP2025524362A (ja) | 2022-06-09 | 2025-07-30 | アルビレオ・アクチボラグ | 肝炎の処置 |
| CA3259103A1 (en) | 2022-07-05 | 2024-01-11 | Albireo Ab | Benzothia (di)azepine compounds and their use as bile acid modulators |
| JP2025539895A (ja) | 2022-12-09 | 2025-12-09 | アルビレオ・アクチボラグ | 腎臓の疾患の治療におけるａｓｂｔ阻害剤 |
| CN121263187A (zh) | 2023-06-06 | 2026-01-02 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 回肠胆汁酸转运蛋白抑制剂用于治疗瘙痒的新用途 |
| WO2025078973A1 (en) | 2023-10-09 | 2025-04-17 | Assia Chemical Industries Ltd. | Solid state forms of linerixibat and process for preparation thereof |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2370015A (en) | 1933-07-24 | 1945-02-20 | Merck & Co Inc | Derivatives of tertiary amino aliphatic acids |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| WO2002053548A1 (fr) * | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20040077625A1 (en) | 2001-07-25 | 2004-04-22 | Tremont Samuel J. | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| AU2003207431A1 (en) * | 2002-01-17 | 2003-09-02 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| AU2004230670B2 (en) | 2003-01-09 | 2010-11-25 | Genentech, Inc. | Purification of polypeptides |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| EP1786813A2 (en) | 2004-09-03 | 2007-05-23 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| JP2012509891A (ja) * | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ，インク． | 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤 |
-
2011
- 2011-04-25 JO JOP/2011/0139A patent/JO3131B1/ar active
- 2011-04-26 UY UY0001033353A patent/UY33353A/es not_active Application Discontinuation
- 2011-04-26 AR ARP110101432A patent/AR081337A1/es active IP Right Grant
- 2011-04-27 WO PCT/US2011/034024 patent/WO2011137135A1/en not_active Ceased
- 2011-04-27 NZ NZ602754A patent/NZ602754A/en unknown
- 2011-04-27 EP EP11775513.2A patent/EP2563122B1/en active Active
- 2011-04-27 MX MX2012012527A patent/MX2012012527A/es active IP Right Grant
- 2011-04-27 RS RS20160709A patent/RS55079B1/sr unknown
- 2011-04-27 ME MEP-2016-160A patent/ME02490B/me unknown
- 2011-04-27 SG SG2012074860A patent/SG184812A1/en unknown
- 2011-04-27 CN CN201180021342.6A patent/CN102858159B/zh active Active
- 2011-04-27 DK DK11775513.2T patent/DK2563122T3/en active
- 2011-04-27 EA EA201290909A patent/EA021753B1/ru not_active IP Right Cessation
- 2011-04-27 CA CA2795543A patent/CA2795543C/en active Active
- 2011-04-27 BR BR112012026767A patent/BR112012026767B1/pt active IP Right Grant
- 2011-04-27 UA UAA201211711A patent/UA110338C2/ru unknown
- 2011-04-27 SI SI201130920A patent/SI2563122T1/sl unknown
- 2011-04-27 US US13/640,166 patent/US9040518B2/en active Active
- 2011-04-27 MA MA35373A patent/MA34235B1/fr unknown
- 2011-04-27 HR HRP20161103TT patent/HRP20161103T1/hr unknown
- 2011-04-27 LT LTEP11775513.2T patent/LT2563122T/lt unknown
- 2011-04-27 ES ES11775513.2T patent/ES2588743T3/es active Active
- 2011-04-27 MY MYPI2012004753A patent/MY162933A/en unknown
- 2011-04-27 PT PT117755132T patent/PT2563122T/pt unknown
- 2011-04-27 HU HUE11775513A patent/HUE029480T2/en unknown
- 2011-04-27 PH PH1/2012/502128A patent/PH12012502128B1/en unknown
- 2011-04-27 KR KR1020127030621A patent/KR101769079B1/ko active Active
- 2011-04-27 PL PL11775513.2T patent/PL2563122T3/pl unknown
- 2011-04-27 JP JP2013508174A patent/JP5702853B2/ja active Active
- 2011-04-27 PE PE2012002082A patent/PE20130384A1/es active IP Right Grant
- 2011-04-27 AU AU2011245393A patent/AU2011245393B2/en active Active
-
2012
- 2012-09-28 CO CO12170751A patent/CO6612267A2/es active IP Right Grant
- 2012-10-04 DO DO2012000263A patent/DOP2012000263A/es unknown
- 2012-10-11 IL IL222365A patent/IL222365A/en active IP Right Grant
- 2012-10-18 ZA ZA2012/07858A patent/ZA201207858B/en unknown
- 2012-10-26 CL CL2012003009A patent/CL2012003009A1/es unknown
- 2012-11-01 CR CR20120557A patent/CR20120557A/es unknown
-
2016
- 2016-08-24 CY CY20161100830T patent/CY1118187T1/el unknown
- 2016-08-29 SM SM201600293T patent/SMT201600293B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02490B (me) | Hemijska jedinjenja | |
| MX358961B (es) | Compuestos de tetraciclina sustituidos con fluor en c7. | |
| HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
| IL198115A (en) | The heteroaryl compounds, their vehicles, and their use in drug preparation | |
| NO20083059L (no) | Pyrimidinderivater | |
| HRP20221018T1 (hr) | Liječenje katapleksije | |
| WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| AR062886A1 (es) | Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| ME02892B (me) | Hemijska jedinjenja | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| NO20084532L (no) | Faste dose formuleringer | |
| MX2013009709A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7. | |
| ME02672B (me) | Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
| WO2010129057A3 (en) | Tetracycline compounds | |
| WO2011025982A3 (en) | Tetracycline compounds | |
| JP2014505017A5 (me) | ||
| WO2011123536A8 (en) | Polycyclic tetracycline compounds | |
| EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
| HRP20221381T1 (hr) | C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta | |
| MY163762A (en) | Therapeutic agent for chronic renal failure |